Jiangsu Hengrui Medicine Co. Ltd., of Lianyungang, China, said it entered a multiyear cancer research agreement with Albert Einstein College of Medicine to develop innovative cancer therapies. The immediate goal is to discover new targets and develop therapies in oncology space. Terms were not disclosed.